Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

Hims & Hers management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Read why HIMS ...

Key Takeaways Hims & Hers Health shares surged Tuesday as the company announced a partnership with Danish drugmaker Novo ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...